+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ankylosing Spondylitis Market - Global Forecast 2025-2030- Product Image
Ankylosing Spondylitis Market - Global Forecast 2025-2030- Product Image
Sale

Ankylosing Spondylitis Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5292911
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Ankylosing Spondylitis Market is rapidly evolving with advancements in diagnostics, therapeutic modalities, and integrated care models providing new opportunities for stakeholders across the life sciences and healthcare sectors.

Market Snapshot: Ankylosing Spondylitis Market

In 2024, the Ankylosing Spondylitis Market was valued at USD 5.60 billion and is projected to reach USD 6.09 billion in 2025, growing at a compound annual growth rate of 8.35% to USD 9.07 billion by 2030. Market activity is influenced by new therapeutic agents, enhanced diagnostic imaging, and shifts in reimbursement policies shaping industry dynamics for manufacturers, providers, and payers.

Scope & Segmentation

This report delivers a comprehensive analysis on the evolving ankylosing spondylitis market landscape. It provides stakeholders with actionable insights through detailed segmentations and coverage of current drivers, emerging challenges, and company innovation profiles. The research scope spans therapeutic strategies, patient populations, and care delivery models as outlined below:

  • Administration Route – Includes injectable (intravenous infusion, subcutaneous injection), intravenous, and oral (capsules, tablets) formulations for disease management.
  • Patient Age Group – Covers adult, geriatric, and pediatric populations, highlighting unique disease considerations and therapy optimization by age segment.
  • End User – Focused on homecare centers, hospitals, and specialty clinics as primary channels influencing modality adoption.
  • Route of Administration – Analyses injectable (intravenous infusion, subcutaneous injection), oral (solutions, tablets), and topical (creams, gels) therapies with an emphasis on clinical preferences.
  • Regional Coverage – Comprehensive analysis across Americas, Europe, Middle East & Africa, and Asia-Pacific, capturing unique growth opportunities and regional challenges within key markets.
  • Key Market Participants – In-depth review of strategies from leading companies such as AbbVie Inc., Novartis AG, Pfizer Inc., Amgen Inc., Eli Lilly and Company, Galapagos NV, Gilead Sciences, Inc., and Sandoz International GmbH.

Key Takeaways

  • The expanding portfolio of disease-modifying treatments is enhancing both symptom management and patient quality of life, while genetic and biomarker advancements are paving the way for precision medicine.
  • Enhanced diagnostic imaging and adoption of wearable and digital health technologies are enabling early intervention and ongoing real-world data collection, improving treatment personalization.
  • Integrated care models—spanning physical therapy, patient education, and mental health support—are being embedded within therapeutic strategies to address the multifaceted burden of the disease.
  • Stakeholders are leveraging collaborative research and development, licensing, and co-development partnerships to accelerate innovation and manage operational risks amid evolving market complexities.
  • Manufacturing scalability and diversification are gaining priority in response to regulatory shifts and supply chain risks, influencing both cost containment strategies and market access.

Tariff Impact: Navigating Supply Chain and Pricing Dynamics

Recent US tariff adjustments in 2025 have introduced economic challenges for therapeutic manufacturers. Industries are responding with measures such as supply chain diversification, cost mitigation through localized production, and adoption of outcome-based pricing models. Collaborative partnerships are helping distribute risk, while ongoing engagement with patient advocates and payers is supporting continuity of patient access despite increased operational costs.

Methodology & Data Sources

This analysis utilizes a robust triangulation approach, integrating qualitative interviews with rheumatologists, payers, and patient advocates, alongside secondary research from peer-reviewed literature and regulatory filings. Quantitative datasets from leading health agencies and prescription monitoring services are cross-validated, while analytical frameworks such as SWOT and Porter’s Five Forces drive strategic forecasting.

Why This Report Matters

  • Empowers decision-makers to evaluate emerging care models, track digital health adoption, and forecast therapeutic adoption across global markets.
  • Equips strategy leaders with actionable segmentation and regional analysis crucial for formulating market entry, expansion, and risk mitigation plans.
  • Delivers up-to-date profiles of key competitors and partnership trends impacting innovation and operational resilience within the ankylosing spondylitis therapeutics ecosystem.

Conclusion

This report offers a strategic blueprint for industry leaders navigating the dynamic Ankylosing Spondylitis Market. Stakeholders who align their operations with precision medicine, digital health, and regional access frameworks will be best positioned for sustained success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of interleukin-17 inhibitors showing enhanced symptom control and reduced radiographic progression in ankylosing spondylitis patients
5.2. Rapid adoption of biosimilar tumor necrosis factor blockers driving cost savings and increased patient access to ankylosing spondylitis therapies
5.3. Integration of telemedicine and remote patient monitoring platforms to improve adherence and early flare detection in AS clinical management
5.4. Advances in personalized treatment algorithms guided by HLA-B27 genotyping and biomarker profiling for targeted ankylosing spondylitis care
5.5. Growing investment in JAK inhibitors for ankylosing spondylitis and evaluation of their long term safety compared to biologics
5.6. Utilization of real world evidence from patient registries to inform long term efficacy and safety profiles of emerging ankylosing spondylitis therapies
5.7. Expansion of value based contracting models between payers and manufacturers to optimize outcomes and control costs in ankylosing spondylitis treatment
5.8. Emerging research into gut microbiome modulation as a novel therapeutic approach for inflammation control in ankylosing spondylitis
5.9. Development of digital physiotherapy and exercise coaching apps to enhance patient engagement and functional outcomes in ankylosing spondylitis care
5.10. Regulatory approvals of next generation small molecule inhibitors broadening the treatment landscape for refractory ankylosing spondylitis cases
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Ankylosing Spondylitis Market, by Administration Route
8.1. Introduction
8.2. Injectable
8.2.1. Intravenous Infusion
8.2.2. Subcutaneous Injection
8.3. Intravenous
8.4. Oral
8.4.1. Capsules
8.4.2. Tablets
9. Ankylosing Spondylitis Market, by Patient Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Ankylosing Spondylitis Market, by End User
10.1. Introduction
10.2. Homecare Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Ankylosing Spondylitis Market, by Route Of Administration
11.1. Introduction
11.2. Injectable
11.2.1. Intravenous Infusion
11.2.2. Subcutaneous Injection
11.3. Oral
11.3.1. Solutions
11.3.2. Tablets
11.4. Topical
11.4.1. Creams
11.4.2. Gels
12. Americas Ankylosing Spondylitis Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Ankylosing Spondylitis Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Ankylosing Spondylitis Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Novartis AG
15.3.3. Pfizer Inc.
15.3.4. Amgen Inc.
15.3.5. Eli Lilly and Company
15.3.6. Galapagos NV
15.3.7. Gilead Sciences, Inc.
15.3.8. Sandoz International GmbH
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ANKYLOSING SPONDYLITIS MARKET: RESEARCHAI
FIGURE 24. ANKYLOSING SPONDYLITIS MARKET: RESEARCHSTATISTICS
FIGURE 25. ANKYLOSING SPONDYLITIS MARKET: RESEARCHCONTACTS
FIGURE 26. ANKYLOSING SPONDYLITIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 111. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 112. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 113. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 114. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 115. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 116. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 117. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 124. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 125. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 126. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 127. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 128. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 129. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 131. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 134. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 135. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 136. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 137. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 144. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 145. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 146. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 221. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 222. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 223. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 224. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 225. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 226. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 227. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 228. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 229. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 234. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 235. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 236. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 237. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 238. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 239. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 240. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 241. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 242. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 243. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 244. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 245. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 252. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 253. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 254. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 255. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 256. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 275. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 276. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 277. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 278. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 279. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 280. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 281. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 282. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 283. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 288. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 289. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 290. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 291. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 292. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 293. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 294. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 295. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 296. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 297. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 298. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 299. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 300. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 301. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 306. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 307. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 308. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 309. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 310. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 330. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 334. SAUDI ARABIA ANKYLOSI

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Sandoz International GmbH

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.09 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.07 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Ankylosing Spondylitis Market Report 2025 - Product Image

Ankylosing Spondylitis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Axial Spondyloarthritis (AXSPA) - Global Strategic Business Report - Product Image

Axial Spondyloarthritis (AXSPA) - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Ankylosing Spondylitis - Pipeline Insight, 2025 - Product Image

Ankylosing Spondylitis - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Ankylosing Spondylitis - Global Strategic Business Report - Product Image

Ankylosing Spondylitis - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From

About the Ankylosing Spondylitis Drug Market

The Ankylosing Spondylitis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Ankylosing Spondylitis is a chronic inflammatory disorder that affects the spine and other joints, and is characterized by pain and stiffness. Ankylosing Spondylitis Drugs are used to reduce inflammation and pain, and to improve mobility. These drugs are typically administered orally or by injection, and may include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The Ankylosing Spondylitis Drug market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include AbbVie, Amgen, Pfizer, Janssen, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.